Advice
Following a full submission.
Sunitinib (Sutent®) is not recommended for use within NHS Scotland for the treatment of advanced and/or metastatic renal cell carcinoma after failure of interferon-alpha or interleukin-2 therapy.
In uncontrolled trials, sunitinib has been associated with tumour responses in patients who have metastatic renal cell cancer. However, the economic case has not been demonstrated.
Download detailed advice94KB (PDF)
Medicine details
- Medicine name:
- sunitinib 50mg capsule (Sutent)
- SMC ID:
- 343/07
- Indication:
- Advanced and/or metastatic renal cell carcinoma
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 12 February 2007